Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc. (COLL)
Filing Type: Form 8-K (Current Report)
Date of Report: February 24, 2022
Reporting Period: This filing announces financial results for the quarterly period and fiscal year ended December 31, 2021. The detailed financial data is contained in the attached press release (Exhibit 99.1) and Earnings Report (Exhibit 99.2), which are furnished but not filed as part of this 8-K text.
Key Financial Metrics
The provided text for this Form 8-K serves as a cover document referencing the release of financial results. It does not contain specific numerical values for the following metrics:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for these metrics; they are located in the referenced exhibits.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only confirms the issuance of a press release regarding the Q4 and full-year 2021 results.
Guidance, Outlook, and Risks
This specific 8-K document does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These items are expected to be detailed in the attached Press Release (Exhibit 99.1) and Earnings Report (Exhibit 99.2).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2021.
- Examine Exhibit 99.2 (Earnings Report) for detailed financial statements and management discussion.
- Verify the company's cash runway and burn rate given the biopharmaceutical sector context.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.